Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Engystol is a branded complex homeopathic medicinal product composed of highly diluted extracts of Vincetoxicum hirundinaria (Asclepias vincetoxicum, white swallow-wort) and elemental sulfur in multiple potencies, formulated primarily as oral tablets and injectable ampoules. It is developed and marketed by Biologische Heilmittel Heel as an over‑the‑counter remedy aimed at activating non‑specific immune defenses to reduce the severity and duration of viral respiratory infections, particularly colds and influenza‑like illnesses, and is also promoted more broadly for upper respiratory infections and recurrent viral conditions by “supporting” endogenous defense mechanisms rather than targeting specific viral proteins.[5][8][10][11][12]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Engystol.